Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up
Open Access
- 20 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-6
- https://doi.org/10.1186/s12885-020-06960-9
Abstract
As aging is the most significant risk factor for cancer development, long-term prostate cancer (PCa) survivors have an evident risk of developing subsequent primary cancers (SPCs). Radiotherapy itself is an additional risk factor for cancer development and the SPCs appearing beyond 5 years after radiotherapy in the original treatment field can be considered as radiation-induced subsequent primary cancers (RISPCs). During the years 1999-2008, 241 patients with localized PCa who underwent low dose-rate brachytherapy (LDR-BT) with I125 and were followed-up in Kuopio University Hospital, were included in this study. In this study the incidences and types of SPCs and RISPCs with a very long follow-up time after LDR-BT were evaluated. During the median follow-up time of 11.4 years, a total of 34 (14.1%) patients developed a metachronous SPC. The most abundant SPCs were lung and colorectal cancers, each diagnosed in six patients (16.7% out of all SPCs). The crude incidence rate of RISPC was 1.7% (n = 4). Half of the SPC cases (50%) were diagnosed during the latter half of the follow-up time as the risk to develop an SPC continued throughout the whole follow-up time with the actuarial 10-year SPC rate of 7.0%. The crude death rates due to metachronous out-of-field SPCs and RISPCs were 50 and 50%, respectively. The crude rate of SPC was in line with previously published data and the incidence of RISPC was very low. These results support the role of LDR-BT as a safe treatment option for patients with localized PCa.Keywords
Funding Information
- Instrumentariumin Tiedesäätiö (Unrestricted research grant)
- Finnish Society of Oncology (Unrestricted research grant)
This publication has 19 references indexed in Scilit:
- Long-Term Efficacy and Toxicity of Low-Dose-Rate 125 I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate CancerInternational Journal of Radiation Oncology*Biology*Physics, 2015
- Incidence of Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical ProstatectomyInternational Journal of Radiation Oncology*Biology*Physics, 2014
- Radiation-Induced Secondary Malignancy in Prostate Cancer: A Systematic Review and Meta-AnalysisUrologia Internationalis, 2014
- Incidence of Second Malignancies for Prostate CancerPLOS ONE, 2014
- Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate CancerClinical Oncology, 2014
- Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment techniqueRadiotherapy and Oncology, 2014
- Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk AnalysisJournal of Clinical Oncology, 2011
- Secondary squamous cell prostate cancer after prostate brachytherapy treatmentScandinavian Journal of Urology and Nephrology, 2011
- Second Primary Cancer After Radiotherapy for Prostate Cancer—A SEER Analysis of Brachytherapy Versus External Beam RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Preface, Main Points, Executive Summary, IntroductionAnnals of the ICRP, 2005